Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Liabilities: 2018-2025

Historic Other Non-Current Liabilities for Summit Therapeutics (SMMT) over the last 6 years, with Sep 2025 value amounting to $1.8 million.

  • Summit Therapeutics' Other Non-Current Liabilities rose 6.64% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 6.64%. This contributed to the annual value of $1.6 million for FY2024, which is 4.35% up from last year.
  • Per Summit Therapeutics' latest filing, its Other Non-Current Liabilities stood at $1.8 million for Q3 2025, which was down 0.44% from $1.8 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Other Non-Current Liabilities high stood at $3.3 million for Q1 2024, and its period low was $1.4 million during Q4 2022.
  • Over the past 3 years, Summit Therapeutics' median Other Non-Current Liabilities value was $1.6 million (recorded in 2024), while the average stood at $1.8 million.
  • Per our database at Business Quant, Summit Therapeutics' Other Non-Current Liabilities plummeted by 48.52% in 2022 and then soared by 123.50% in 2024.
  • Quarterly analysis of 5 years shows Summit Therapeutics' Other Non-Current Liabilities stood at $2.8 million in 2021, then crashed by 48.52% to $1.4 million in 2022, then grew by 9.31% to $1.6 million in 2023, then increased by 4.35% to $1.6 million in 2024, then increased by 6.64% to $1.8 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.8 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.7 million for Q1 2025.